News & Updates

Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?

20 Oct 2022 by

Updated results of the SUGAR* trial showed that using polymer-free amphilimus-eluting stents (AES) was not a superior option to durable-polymer zotarolimus-eluting stents (ZES) in patients with diabetes mellitus who required percutaneous coronary intervention (PCI).

Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?

20 Oct 2022

Asundexian for secondary prevention after acute MI scores high in early trial

20 Oct 2022

The oral activated factor XI (FXIa) inhibitor asundexian, when taken with aspirin plus a P2Y12 inhibitor, appears to facilitate dose-dependent, near-complete inhibition of FXIa activity with a low rate of ischaemic events and without a significant increase in bleeding, according to the results of a phase II trial.

Asundexian for secondary prevention after acute MI scores high in early trial

20 Oct 2022

Circulating T cells tied to CVD risk in people with HIV infection

20 Oct 2022 by

Subsets of peripheral circulating CD4 T cell among people with HIV infection (PWH) are predictive of incident cardiovascular disease (CVD), including heart failure and atherosclerotic CVD, reveals a study.

Circulating T cells tied to CVD risk in people with HIV infection

20 Oct 2022

High egg intake poses no risk of cardiovascular events

19 Oct 2022

People who like eating eggs do not seem to be at higher risk of myocardial infarction (MI), ischaemic coronary heart disease (ICHD), stroke, and cardiovascular disease (CVD), suggests the results of a recent study in Iran.

High egg intake poses no risk of cardiovascular events

19 Oct 2022

Rivaroxaban cuts radial artery occlusion rates

19 Oct 2022 by

Rivaroxaban reduces radial artery occlusion rate, without significantly increasing bleeds, in patients undergoing transradial coronary procedures in the RIVARAD study.

Rivaroxaban cuts radial artery occlusion rates

19 Oct 2022

Weight change in diabetic adults hints at adverse cardiovascular events

18 Oct 2022

Patients with type 2 diabetes (T2D) who have gained or lost weight over 18 months, particularly a ≥5-percent change in weight, are probably at an increased risk of adverse cardiovascular outcomes, suggests a study.

Weight change in diabetic adults hints at adverse cardiovascular events

18 Oct 2022

Foetal growth restriction, prematurity tied to higher BP in children

18 Oct 2022

Among school-aged children, having been born premature and with foetal growth restriction (FGR) appears to be associated with higher systolic blood pressure (SBP) and augmentation index (AIx), a new study has found.

Foetal growth restriction, prematurity tied to higher BP in children

18 Oct 2022

Alirocumab prior to PCI lowers LDL-C

18 Oct 2022 by

Starting alirocumab early in the hospital prior to undergoing percutaneous coronary intervention (PCI) reduces LDL-cholesterol (LDL-C) in STEMI* patients already on high-statin therapy.

Alirocumab prior to PCI lowers LDL-C

18 Oct 2022

Multimodal thrombectomy device holds promise in DVT treatment

17 Oct 2022 by

A novel thrombectomy device using a sequestered approach delivers positive clinical outcomes in the treatment of high-risk, large-volume deep vein thrombosis (DVT), according to a study.

Multimodal thrombectomy device holds promise in DVT treatment

17 Oct 2022

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

News & Updates

Filter by Specialty:

Specialty:

Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?

Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?

Asundexian for secondary prevention after acute MI scores high in early trial

Asundexian for secondary prevention after acute MI scores high in early trial

Circulating T cells tied to CVD risk in people with HIV infection

Circulating T cells tied to CVD risk in people with HIV infection

High egg intake poses no risk of cardiovascular events

High egg intake poses no risk of cardiovascular events

Rivaroxaban cuts radial artery occlusion rates

Rivaroxaban cuts radial artery occlusion rates

Weight change in diabetic adults hints at adverse cardiovascular events

Weight change in diabetic adults hints at adverse cardiovascular events

Foetal growth restriction, prematurity tied to higher BP in children

Foetal growth restriction, prematurity tied to higher BP in children

Alirocumab prior to PCI lowers LDL-C

Alirocumab prior to PCI lowers LDL-C

Multimodal thrombectomy device holds promise in DVT treatment

Multimodal thrombectomy device holds promise in DVT treatment

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)